We are live on ! Find out more

Revvity

RVTY

Market cap $17.5B

157.00 USD

-8.78

5.3%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

159.04

+2.04

1.3%

1 day

-5.3%

5 days

-1.49%

1 month

2.69%

3 months

38.28%

6 months

81.25%

Year to date

59.96%

1 year

72.49%

5 years

-10.98%

10 years

208.51%

About: Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Employees: 11,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 47.4%

Neutral 50%

Negative 2.6%

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 12, 2027 to all shareholders of record at the close of business on January 22, 2027. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.

Revvity Board Declares Quarterly Dividend

Zacks Investment Research

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

Zacks Investment Research

GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.

GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

Zacks Investment Research

Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

ELV vs. RVTY: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?

ELV vs. RVTY: Which Stock Is the Better Value Option?

Zacks Investment Research

Revvity Launches Signals LabGistics to Coordinate Scientific Workflows

RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.

Revvity Launches Signals LabGistics to Coordinate Scientific Workflows

Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine

Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while software ARR grew in the mid-20% range, offsetting Life Sciences weakness and China exit headwinds. Operating leverage is strong, with 13% EPS growth on 3% organic revenue growth and free cash flow conversion exceeding 100%, supporting deleveraging and strategic reinvestment.

Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. The Signals LabGistics offering uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. As.

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

See News Rankings

Price charts implemented using Lightweight Charts™